Mineralys Therapeutics (MLYS) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 213.9% versus a loss of 67.4%. Silence Therapeutics Plc American Depository Share is the larger company by market cap ($1.23 billion vs $1.21 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | SLN |
|---|---|---|
| Share price | $13.66 | $19.81 |
| Market cap | $1.21B | $1.23B |
| 1-day change | -3.53% | 0.00% |
| YTD return | -62.36% | +225.82% |
| 1-year return | -67.38% | +213.95% |
| 5-year return | — | -9.95% |
| EPS (TTM) | $-4.30 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $559.00K |
| Revenue growth (YoY) | — | -98.71% |
| Net income (latest FY) | $-154.65M | $-88.61M |
| Gross margin | — | 61.54% |
| Operating margin | — | -16292.84% |
| Net margin | — | -15851.88% |
| 52-week high | $44.13 | $19.87 |
| 52-week low | $13.57 | $4.19 |
| Distance from 52-week high | -69.05% | -0.28% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +218.89% | -0.30% |
| Average volume | 1.55M | 2.41M |
| Shares outstanding | 88.56M | 62.20M |
| Employees | 76 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed MLYS by 281.3 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
MLYS vs SLN FAQ
Which is bigger, Mineralys Therapeutics or Silence Therapeutics Plc American Depository Share?
Silence Therapeutics Plc American Depository Share (SLN) is larger, with a market capitalization of $1.23B compared with $1.21B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, MLYS or SLN?
SLN returned +213.95% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Silence Therapeutics Plc American Depository Share in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.